Obesity News
🇺🇸 FDAFDA breaking news and regulatory updates for BD, investors, and analysts
Showing 1–12 of 19 articles
Chile warning labels on food: new evidence on efficacy and obesity risk
GLP-1 usage statistics show broad uptake and mixed clinical signals
MariTide Phase 2 obesity data show up to 20% weight loss at one year
Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win
MariTide Phase 2: Amgen reports up to 20% weight loss at one year
Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint
Triple Hormone-Receptor Agonist Retatrutide for Obesity: Phase 3 Results and Market Impact
Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook
Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
MIRA Pharma Consolidates Global Rights to MIRA-55 and SKNY-1
Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment